Han Dong, Zhao Zheng, Mao Tinghui, Gao Man, Yang Xue, Gao Yan
Department of Neurology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Department of Emergency Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
CNS Neurosci Ther. 2024 Dec;30(12):e70150. doi: 10.1111/cns.70150.
Depression, a widespread mental disorder, presents significant risks to both physical and mental health due to its high rates of recurrence and suicide. Currently, single-target antidepressants typically alleviate depressive symptoms or delay the progression of depression rather than cure it. Ginsenoside Rg1 is one of the main ginsenosides found in Panax ginseng roots. It improves depressive symptoms through various mechanisms, suggesting its potential as a treatment for depression.
We evaluated preclinical studies to comprehensively discuss the antidepressant mechanism of ginsenoside Rg1 and review its toxicity and medicinal value. Additionally, pharmacological network and molecular docking analyses were performed to further validate the antidepressant effects of ginsenoside Rg1.
The antidepressant mechanism of ginsenoside Rg1 may involve various pharmacological mechanisms and pathways, such as inhibiting neuroinflammation and over-activation of microglia, preserving nerve synapse structure, promoting neurogenesis, regulating monoamine neurotransmitter levels, inhibiting hyperfunction of the hypothalamic-pituitary-adrenal axis, and combatting antioxidative stress. Moreover, ginsenoside Rg1 preserves astrocyte gap junction function by regulating connexin43 protein biosynthesis and degradation, contributing to its antidepressant effect. Pharmacological network and molecular docking studies identified five targets (AKT1, STAT3, EGFR, PPARG, and HSP90AA1) as potential molecular regulatory sites of ginsenoside Rg1.
Ginsenoside Rg1 may exert its antidepressant effects via various pharmacological mechanisms. In addition, multicenter clinical case-control and molecular targeted studies are required to confirm both the clinical efficacy of ginsenoside Rg1 and its potential direct targets.
抑郁症是一种广泛存在的精神障碍,因其高复发率和自杀率对身心健康构成重大风险。目前,单靶点抗抑郁药通常只能缓解抑郁症状或延缓抑郁症的进展,而非治愈。人参皂苷Rg1是人参根中主要的人参皂苷之一。它通过多种机制改善抑郁症状,表明其具有治疗抑郁症的潜力。
我们评估了临床前研究,以全面探讨人参皂苷Rg1的抗抑郁机制,并综述其毒性和药用价值。此外,还进行了药理网络和分子对接分析,以进一步验证人参皂苷Rg1的抗抑郁作用。
人参皂苷Rg1的抗抑郁机制可能涉及多种药理机制和途径,如抑制神经炎症和小胶质细胞过度活化、保留神经突触结构、促进神经发生、调节单胺类神经递质水平、抑制下丘脑-垂体-肾上腺轴功能亢进以及对抗氧化应激。此外,人参皂苷Rg1通过调节连接蛋白43的生物合成和降解来保留星形胶质细胞间隙连接功能,这有助于其抗抑郁作用。药理网络和分子对接研究确定了五个靶点(AKT1、STAT3、EGFR、PPARG和HSP90AA1)为人参皂苷Rg1潜在的分子调控位点。
人参皂苷Rg1可能通过多种药理机制发挥其抗抑郁作用。此外,需要多中心临床病例对照和分子靶向研究来证实人参皂苷Rg1的临床疗效及其潜在的直接靶点。